Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer

Tumor evolution is shaped by many variables, potentially involving external selective pressures induced by therapies1. After surgery, estrogen receptor (ERα) positive breast cancer (BCa) patients are treated with adjuvant endocrine therapy2 including selective estrogen receptor modulators (SERMs) an...

Full description

Saved in:
Bibliographic Details
Published in:Nat Genet
Main Authors: Magnani, Luca, Frige, Gianmaria, Gadaleta, Raffaella Maria, Corleone, Giacomo, Fabris, Sonia, Kempe, Mannus H., Vershure, Pernette J., Barozzi, Iros, Vircillo, Valentina, Hong, Sung-Pil, Perone, Ylenia, Saini, Massimo, Trumpp, Andreas, Viale, Giuseppe, Neri, Antonino, Ali, Simak, Colleoni, Marco Angelo, Pruneri, Giancarlo, Minucci, Saverio
Format: Artigo
Language:Inglês
Published: 2017
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5326683/
https://ncbi.nlm.nih.gov/pubmed/28112739
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ng.3773
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items